Biochemical tolerance during low dose propylene glycol exposure in neonates: A formulation-controlled evaluation

DARU, Journal of Pharmaceutical Sciences

Volumn 20, Issue 1, 2012, Pages

  Kulo, Aida ^a,b   Smits, Anne ^a   Naulaers, Gunnar ^a   De Hoon, Jan ^a   Allegaert, Karel ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

Author keywords

Excipient; Formulation; Propylene glycol; Safety; Solvent; Tolerance

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BASE; BICARBONATE; BILIRUBIN; CREATININE; DIGOXIN; LACTIC ACID; MANNITOL; PARACETAMOL; PARACETAMOL SYNTHETICA; PERFUSALGAN; PHENOBARBITAL; PHENYTOIN; PROPYLENE GLYCOL; SODIUM; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALOSIS; ANION GAP; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BICARBONATE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CREATININE BLOOD LEVEL; DIURESIS; DRUG EXPOSURE; DRUG FORMULATION; HUMAN; HYPERBILIRUBINEMIA; LIVER METABOLISM; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; NEWBORN; PERINATAL PERIOD; PHYSICAL TOLERANCE; RENAL SYSTEM PARAMETERS; SODIUM URINE LEVEL;

EID: 84867006025     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/1560-8115-20-5     Document Type: Article

References (18)

1. Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving iv benzodiazepines: a case series and prospective, observational pilot study. Wilson KC, Reardon C, Theodore AC, Farber HW, Chest 2005 128 1674 1681 10.1378/chest.128.3.1674 16162774 (Pubitemid 41324463)
2. Recognition, treatment, and prevention of propylene glycol toxicity. Zar T, Graeber C, Perazella MA, Semin Dial 2007 20 217 219 10.1111/j.1525-139X.2007. 00280.x 17555487
3. Propylene glycol pharmacokinetics and effects after intravenous infusion in humans. Speth PA, Vree TB, Neilen NF, de Mulder PH, Newell DR, Gore ME, de Pauw BE, Ther Drug Monit 1987 9 255 258 10.1097/00007691-198709000-00001 3672566 (Pubitemid 17149385)
4. A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patients. Nelsen JL, Haas CE, Habtemariam B, Kaufman DC, Partridge A, Welle S, Forrest A, J Intensive Care Med 2008 23 184 194 10.1177/0885066608315808 18543419 (Pubitemid 351667152)
5. Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene glycol toxicity. Yahwak JA, Riker RR, Fraser GL, Subak-Sharpe S, Pharmacotherapy 2008 28 984 991 10.1592/phco.28.8.984 18657015
6. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Shehab N, Lewis CL, Streetman DD, Donn SM, Pediatr Crit Care Med 2009 10 256 259 10.1097/PCC.0b013e31819a383c 19188870
7. Propylene glycol accumulation associated with continuous infusion of lorazepam in pediatric intensive care patients. Chicella M, Jansen P, Parthiban A, Marlowe KF, Bencsath FA, Krueger KP, Boerth R, Crit Care Med 2002 30 2752 2756 10.1097/00003246-200212000-00021 12483068 (Pubitemid 36870579)
8. Propylene glycol: increased incidence of seizures in low birth weight infants. MacDonald MG, Getson PR, Glasgow AM, Miller MK, Boeckx RL, Johnson EL, Pediatrics 1987 79 622 625 3822682 (Pubitemid 17051431)
9. Hyperosmolality in small infants due to propylene glycol. Glasgow AM, Boeckx RL, Miller MK, MacDonald MG, August GP, Goodman SI, Pediatrics 1983 72 353 355 6889040 (Pubitemid 13051212)
10. Kaletra revisions to packaging approved. FDA notifications, AIDS Alert 2010 25 34 20632456
11. Prospective assessment of short-term propylene glycol tolerance in neonates. Allegaert K, Vanhaesebrouck S, Kulo A, Cosaert K, Verbesselt R, Debeer A, de Hoon J, Arch Dis Child 2010 95 1054 1058 10.1136/adc.2010.190330 20959360
12. The pharmacokinetics of intravenous paracetamol in neonates: size matters most. Allegaert K, Palmer GM, Anderson BJ, Arch Dis Child 2011 96 575 580 10.1136/adc.2010.204552 21317433
13. Hepatic tolerance of repeated intravenous paracetamol administration in neonates. Allegaert K, Rayyan M, de Rijdt T, van Beek F, Naulaers G, Paediatr Anaesth 2008 18 388 392 10.1111/j.1460-9592.2008.02535.x 18384338 (Pubitemid 351490493)
14. Intra- and interindividual variability of glucuronidation of paracetamol during repeated administration of propacetamol in neonates. Allegaert K, de Hoon J, Verbesselt R, Vanhole C, Devlieger H, Tibboel D, Acta Paediatr 2005 94 1273 1279 16278989 (Pubitemid 41510625)
15. Toxic additives in medication for preterm infants. Whittaker A, Currie AE, Turner MA, Field DJ, Mulla H, Pandya HC, Arch Dis Child Fetal Neonatal Ed 2009 94 236 F240 10.1136/adc.2008.146035 19158148
16. Determination of propylene glycol in low volume plasma and urine samples of neonates by LC with photodiode array detection. Kulo A, Allegaert K, de Hoon J, Verbesselt R, Chromatographia 2011 73 463 470 10.1007/s10337-011-1923-8
17. Developmental pharmacology: neonates are not just small adults. Allegaert K, Verbesselt R, van den Anker JN, Rayyan M, Debeer A, Naulaers G, de Hoon J, Acta Clin Belg 2008 63 16 24 18386761 (Pubitemid 351311069)
18. The role of population PK-PD modelling in paediatric clinical research. de Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA, Eur J Clin Pharmacol 2011 67 Suppl 1 5 16 20340012